Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
13.51
-0.49 (-3.50%)
At close: Feb 20, 2026, 4:00 PM EST
13.65
+0.14 (1.04%)
After-hours: Feb 20, 2026, 5:21 PM EST
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$558,167
Profits / Employee
-$596,142
Market Cap
392.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Rocket Pharmaceuticals | 299 |
| Entrada Therapeutics | 183 |
| Absci | 157 |
| Century Therapeutics | 150 |
| Niagen Bioscience | 104 |
| Assembly Biosciences | 73 |
| PureTech Health | 56 |
ENTA News
- 11 days ago - Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Business Wire
- 12 days ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - Business Wire
- 5 weeks ago - Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development - Seeking Alpha
- 3 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire